semaglutide alcohol use disorder A clinical trial from the University of Colorado Anschutz found oral semaglutide, the medication behind Ozempic and Wegovy, can reduce heavy drinking in adults with disorder. Read more: https://www.forbes.com/sites/antoniopequenoiv/2026/07 GLP-1 reduces heavy drinking days

For now, topical GHK-Cu remains the most effective way to harness its benefits

Meanwhile, GLP-1 receptor activation in the hypothalamus, specifically in the arcuate nucleus and paraventricular nucleus, directly suppresses hunger signals by activating satiety-promoting POMC/CART neurons while inhibiting hunger-promoting NPY/AgRP neurons

In September, Pfizer offered to buy Metsera for $4.9 billion, but less than a month later, Novo Nordisk made an unsolicited bid of $6.0 billion in cash

Semaglutide is a medication that has become an important option for people trying to lose weight

Compounded tirzepatide formulations may also be available when prescribed by a licensed provider based on individual patient needs